Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Freedom Finance and Binance Join Forces in Digital Assets 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
CHESTERBROOK, Pa., April 26, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Thursday, May 3, 2018 at 8:00 am EDT to review financial results for the quarter ended March 31, 2018 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 1350009).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 1350009). Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
